You are here

The Progress Report Progress never stops. Stay informed with the latest news on breast cancer research, treatment, and prevention.

Tag:

Metastatic Research x

Hormone Receptor Positive Breast Cancer: CDK4/6 inhibitors 

BCRF previously reported on updates of a new class of drugs called CDK4/6 inhibitors in clinical trials for hormone receptor positi

Metastasis is a complicated process with many steps, beginning with the breast cancer cells breaking away from the primary tumor and entering the blood or lymphatic system. Not every tumor cell that that enters the circulation, however will form a tumor somewhere else in the body.

One major challenge faced by academic researchers in advancing urgently needed treatment options has been the lack of access to new drugs in development.

This October, Lokai adds to their collection of trademark bracelets by offering a limited-edition hot pink bracelet in support of BCRF. One dollar of each Breast Cancer Lokai purchased will support the Foundation’s mission to fund critical breast cancer research.

Metastasis, when cancer cells leave the breast and spread to other sites in the body, is the major cause of mortality from breast cancer. Common sites of breast cancer metastasis are bone, lung, liver and brain.

A recent article in The Wall Street Journal, “Researchers Take Aim at Metastatic Breast Cancer,” (published Feb. 15) touched on a pervasive problem in cancer research today.

BCRF investigator Andrew Ewald, PhD, Associate Professor of Cell Biology and Member of the Kimmel Cancer Center at Johns Hopkins University School of Medicine, conducts research in metastatic breast cancer, focusing on the molecular and